Predicting liver failure after major liver surgery using CT measurements and vascular shape changes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, observational study examines adults planned for major hepatectomy (removal of three or more liver segments). It adds hepatic vascular deformation mapping to standard CT volumetry to see if it improves prediction of post-hepatectomy liver failure. The goal is to identify patients at higher risk so surgeons can tailor plans or provide additional care. The study uses preoperative imaging and follows patients for at least 30 days after surgery. It is sponsored by Minia University with collaboration from regional institutions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Scheduled to undergo major hepatic resection, defined as the removal of three or more Couinaud segments, at a participating center
* Availability of a preoperative multiphasic contrast-enhanced CT of the liver of quality sufficient for central core-laboratory analysis
* Willing and able to complete postoperative clinical and laboratory follow-up for at least 30 days
* Written informed consent

Exclusion Criteria:

* Minor hepatic resection (fewer than three Couinaud segments)
* Significant pre-existing vascular anomaly or vascular pathology (for example, portal vein thrombosis)
* Emergency hepatic resection for trauma
* Preoperative imaging that fails central quality control
* Incomplete follow-up data

Where it's running

• Liver and GIT Hospital, Faculty of Medicine, Minia University
  Minya, Minya Governorate, Egypt Recruiting
• Maadi Armed Forces Medical Compound - Department of Liver and Pancreas Surgery and Liver Transplantation
  Maadi, Egypt Recruiting
• National Liver Institute, Menoufia University
  Shibīn al Kawm, Egypt Recruiting

Study contacts

• Principal investigator: Saleh K Saleh, MD — Minia University
• Study coordinator: Saleh K Saleh, MD
• Email: salehkhairy@mu.edu.eg
• Phone: 01201765401

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• PF-08634404 alone or with ipilimumab for adults with advanced hepatocellular carcinoma not removable by surgery

  This tests PF-08634404 by itself and together with ipilimumab in adults whose hepatocellular carcinoma is advanced and cannot be removed surgically.

  Recruiting at 60 sites Phase 1/2 Pfizer · Irvine, California and 59 other locations · NCT07227012

• CRISPR-edited donor liver transplant to reduce rejection

  This trial will try transplanting deceased-donor livers that have had key HLA genes removed with CRISPR to see if they cause less rejection in adults needing a liver transplant.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053488

• Multimodal ablation with Tislelizumab, lenvatinib and TACE for unresectable primary liver cancer

  This trial will test whether combining multimodal ablation with Tislelizumab (a PD‑1 antibody), lenvatinib, and TACE helps people with unresectable primary liver cancer.

  Recruiting Shanghai Zhongshan Hospital · Shanghai, Shanghai Municipality · NCT06794073

• Evaluating AST-201 for GPC3-positive advanced solid tumors

  This study is testing a new treatment called AST-201 to see if it can help people with advanced solid tumors that have a specific marker called GPC3.

  Recruiting at 4 sites Phase 1 Aptamer Sciences, Inc. · Goyang-si, Gyeonggi-do and 3 other locations · NCT06687941

• Comparing methods to increase liver size before surgery

  This study is testing three different ways to help increase liver size before surgery for patients with liver tumors to see which method works best.

  Recruiting Medical University of Warsaw · Warsaw, Masovian Voivodeship · NCT06050200

• Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes

  This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.

  Recruiting at 14 sites UMC Utrecht · Pittsburgh, Pennsylvania and 17 other locations · NCT04075305

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.